Nirmal Bang has recommended hold rating on Glenmark Pharmaceuticals with a target price of Rs 358, in its November 18, 2011 research report.
Glenmark Pharmaceuticals reported better than expected total income with 42% yoy growth at Rs 1055.7 crs including outlicensing income of Rs
118.5 crs. Excluding that, also the sales growth was impressive 29.4% at Rs 937 crs. However, due to onetime royalty payment to Paul Capital of Rs 131.7 crs net profit showed a decline of 50% yoy at Rs 55.9 crs.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
Read More
